AI-generated summary
In this split-face study, 30 patients with photoaging received five sessions of either a fractional 1064 nm picosecond laser or a fractional Q-switched 1064 nm laser on each side of the face. The authors report improvements in wrinkles, pores and skin texture for both lasers with no significant difference between them, and the picosecond side caused more pain.
- Participants
- 30
- Who or what was studied
- Thirty patients with facial photoaging, each treated on both sides of the face (split-face design)
- Wavelengths
- 1064 nm
- Limits stated in the abstract
- The abstract describes a single split-face trial with no details on follow-up dropout, and the authors state that FxPico may offer superior collagen stimulation without establishing a clinical difference.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Facial photoaging is a complex biological process influenced by both internal and external factors. It is characterized by wrinkles, enlarged pores, and rough skin. Despite various clinical treatments, they often have limited effectiveness, significant side effects, and extended recovery times. There is a need for more effective and safer treatment options. Preliminary evidence suggests significant differences in mechanisms between fractional 1064 nm Nd:YAG picosecond laser (FxPico) and fractional Q-switched 1064-nm Nd:YAG laser (QSF-Nd:YAG). Photothermal tissue modulation is achieved in the QSF-Nd:YAG platform through holographic beam splitting, whereas the FxPico system's microlens arrays (MLA) enable dual-mode action through concurrent photothermal and laser-induced optical breakdown (LIOB) mechanisms. The purpose of this study was to conduct a split-face controlled trial on the same subject, observing the therapeutic effects of both modalities.
Methods
Thirty patients with photoaging underwent five treatment sessions at weeks 0, 2, 4, 6, and 8. Each patient received FxPico on one side of the face and QSF-Nd:YAG on the other. Follow-up evaluations were conducted at 1 and 3 months post-treatment. Efficacy was assessed using VISIA quantitative analysis, reflectance confocal microscopy (RCM), and histological examination. Safety was evaluated based on adverse events and patient-reported pain.
Results
Among the patients following the completion of five treatment sessions exhibited remarkable improvement in terms of facial wrinkles, pores and skin texture from VISIA quantitative numerical assessment (p < 0.001). Semi-quantitative assessments from reflectance confocal microscopy analysis also demonstrated a significant decrease (p < 0.05). There were no statistically significant differences observed in the reduction rates of wrinkles, pores, skin texture counts, semi-quantitative scores, and the Global Aesthetic Improvement Scale scores (p > 0.05) between the FxPico and QSF-Nd:YAG sides. Histological analysis revealed increased collagen formation and improved elastic fiber alignment in both treatment groups, which objectively validates the therapeutic efficacy of both laser modalities for photoaging. Adverse events were mild, with FxPico causing more pain (p < 0.0001).
Conclusion
Both FxPico and QSF-Nd:YAG lasers are effective and safe for improving photoaging, with no significant differences in clinical outcomes. FxPico may offer superior collagen stimulation, albeit with higher pain levels.
Trial Registration
China Clinical Trial Registry: ChiCTR2200058566.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 1064 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Laser, Collagen, Trial registration. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.